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Abstract: Diagnoses based on oral fluid biomarkers have been introduced to overcome limitations
of periodontal probe-based diagnoses. Diagnostic ability of certain biomarkers for periodontitis
have been identified and widely studied, however, such studies targeting gingivitis is scarce.
The aims of this study were to determine and compare the efficacies and accuracies of eight
biomarkers in diagnosing gingivitis with the aid of receiver operating characteristic (ROC) curves.
The probing depth (PD), clinical attachment loss (CAL), bleeding on probing (BOP), gingival index
(GI), and plaque index (PI) were examined in 100 participants. Gingival crevicular fluid was collected
using paper points, and whole-saliva samples were collected using cotton roll. Samples were
analyzed using enzyme-linked immunosorbent assay kits for the different biomarkers. The levels
of matrix metalloproteinase (MMP)-8, MMP-9, lactoferrin, cystatin C, myeloperoxidase (MPO),
platelet-activating factor, cathepsin B, and pyridinoline cross-linked carboxyterminal telopeptide
of type I collagen were analyzed. MPO and MMP-8 levels in saliva were strongly correlated with
gingivitis, with Pearson’s correlation coefficients of 0.399 and 0.217, respectively. The area under the
curve (AUC) was largest for MMP-8, at 0.814, followed by values of 0.793 and 0.777 for MPO and
MMP-9, respectively. The clinical parameters of GI and PI showed strong correlations and large AUC
values, whereas PD and CAL did not. MMP-8 and MPO were found to be effective for diagnosing
gingivitis. Further investigations based on the results of this study may identify clinically useful
biomarkers for the accurate and early detection of gingivitis.
Keywords: gingivitis; matrix metalloproteinase-8 (MMP-8); myeloperoxidase (MPO); biomarker; diagnosis
1. Introduction
Periodontitis is a complex inflammatory reaction against a dysbiotic challenge that results in the
irreversible loss of periodontal supporting tissues. The high global prevalence of periodontitis results in
a high burden in terms of productivity loss and the costs of treating oral disease [1,2]. Since gingivitis is
considered a prerequisite to periodontitis, early intervention through the accurate and early diagnosis
of the gingivitis state is an effective approach for preventing periodontitis [3].
Periodontal disease is conventionally diagnosed based on measurements of clinical attachment
loss (CAL) and bleeding on probing (BOP) using a periodontal probe. However, periodontal probing
involves pain to patients and has standardization limitations due to variations of the insertion
pressure and angle between clinicians [4,5]. Moreover, CAL can only be measured after the significant
breakdown of more than 2 mm of periodontal tissue has occurred, and it only shows the history of
disease progression rather than demonstrating the present inflammatory state of the disease [6].
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The use of biomarkers in oral fluids such as saliva and gingival crevicular fluid (GCF) has been
suggested for overcoming the limitations of probing-based diagnoses of periodontal disease [7–9].
Cytokines and proteins involved in host responses are potentially useful biomarkers as they directly
reflect the current inflammatory state of the periodontal tissue [10]. Moreover, saliva and GCF are
easy to collect from patients and contain various biomarkers, which has resulted in numerous studies
suggesting the use of various oral fluid biomarkers for diagnosing periodontal disease.
Previous studies have suggested the following possible biomarkers for periodontal disease: matrix
metalloproteinase (MMP)-8, MMP-9, lactoferrin, cystatin C, myeloperoxidase (MPO), platelet-activating
factor (PAF), cathepsin B, and pyridinoline cross-linked carboxyterminal telopeptide of type I
collagen (ICTP) [11–15]. MMP-8, MMP-9, MPO, and cathepsin B are tissue destructive enzymes
that are activated in inflammatory cascade, and ICTP is a bone degradation marker. Lactoferrin,
cystatin C and PAF are known as markers for chronic inflammation. Thus, it is obvious that these
biomarkers are pathophysiologically related to periodontal inflammation. However, while the level
of each of these biomarkers differed significantly between disease and normal groups in previous
studies, such significant differences do not directly indicate that the biomarkers have clinically useful
diagnostic power.
Receiver operating characteristic (ROC) curves have been used in medicine to identify the
effectiveness and power of biomarkers for the differential diagnosis of disease. ROC curves plot the
sensitivity versus the specificity of each biomarker, and they can be used to compare the diagnostic
capabilities of biomarkers based on the area under the curve (AUC). These curves are especially
effective in comparing the diagnostic capabilities of biomarkers on different units [16].
Previous studies have demonstrated that MMP-8, MMP-9, lactoferrin, cystatin C, MPO, PAF,
cathepsin B, and ICTP can be used to diagnose periodontitis. However, to the best of our knowledge,
few studies have investigated the correlations between these biomarkers and gingivitis. In addition to
early detection of gingivitis, confirming biomarkers of gingivitis can be the basis for future studies
regarding gingival health state and individual variation of disease susceptibility. Thus, the aims of this
study were to: (1) determine the efficacies and accuracies of eight biomarkers in diagnosing gingivitis,
and (2) compare the diagnostic abilities of the biomarkers using ROC curves.
2. Materials and Methods
2.1. Study Design and Population
One hundred and six voluntary participants were recruited at the clinic of the Department of
Periodontology, Yonsei University Dental Hospital. The study was conducted in accordance with the
Declaration of Helsinki and approved by the Institutional Review Board of Yonsei University Dental
Hospital (Approval number: 2-2016-0044). Each voluntary participant was given verbal and written
information about the study and then signed an informed consent form before being enrolled in the
study. The study design is illustrated in Figure 1. Before enrollment, all volunteers were clinically
examined and interviewed in accordance with the inclusion and exclusion criteria listed below.
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Figure 1. Flowchart and study protocol. GCF, gingival crevicular fluid; ELISA, enzyme-linked
immunosorbent assay.
2.2. Inclusion and Exclusion Criteria
The inclusion criteria were: (1) being >18 and <80 years of age and in good general health,
(2) having a minimum of 18 teeth, (3) having less than 5 mm of CAL at the first visit, and (4) being
diagnosed as chronic gingivitis or periodontal health according to the consensus report of the 2017
world workshop [17]. The exclusion criteria were: (1) not providing written informed consent,
(2) being pregnant or lactating, (3) having a severe systemic disease such as uncontrolled diabetes or
hypertension, (4) having enrolled in another clinical study within the previous three months, (5) taking
antiplatelet agents or anticoagulants or having a history of hemorrhage or disease, (6) taking an
antibiotic within the previous month, (7) having an oral mucosal inflammatory condition (e.g., lichen
planus or leukoplakia), or (8) judged as being inappropriate for study inclusion for some other reason
by the clinician.
2.3. Clinical Evaluation
A clinician in the clinic at the Department of Periodontology measured periodontal parameters in
the following six representative teeth for each subject: #16, #21, #24, #36, #41, and #44. The probing
depth (PD), BOP, and CAL were measured at mesiobuccal, midbuccal, distobuccal, mesiolingual,
midlingual, and distolingual sites for each tooth. The gingival index (GI) and plaque index (PI) were
also measured for each tooth based on Turesky et al. [18].
In accordance with the consensus report of the 2017 World Workshop, patients exhibiting BOP
at more than 10% of the investigated sites were diagnosed as gingivitis [17]. Since six sites of the
representative six teeth were examined for BOP in this study, patients who had more than four BOP
sites were classified into the gingivitis group.
2.4. GCF and Saliva Collection
Methods for collecting GCF and saliva were set up based on previous studies [9,19]. Patients
were asked to fast at least 8 h before visiting the clinic. The site at which GCF was collected was dried
with an air syringe and isolated from salivary and blood contamination with the aid of cotton rolls
or mirror retraction. Supragingival plaques were carefully removed using gauze and paper points
(Dia-Pro ISO.04, DiaDent, Cheongju, Korea) that were gently inserted into the gingival crevice mesial,
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midbuccal, and distal of representative three teeth (#16, #24, and #36). The paper points were removed
after 30 s and then stored together in a centrifuge tube, into which 300 µl of phosphate-buffered saline
was added before being incubated at 4 ◦C overnight. After centrifugation at 3000× g for 5 min at 4 ◦C,
the clear supernatant was extracted and stored at –80 ◦C until being analyzed.
Patients rinsed their mouths with pure water prior to saliva collection. Whole-saliva samples
were then collected by keeping cotton rolls in the mouth for 60 s, which were then stored in a centrifuge
tube. After centrifugation at 3000× g for 10 min, a clear saliva sample yielded in a conical tube was
stored at –80 ◦C until being analyzed.
2.5. Enzyme-Linked Immunosorbent Assay Analysis of Molecular Biomarkers
Enzyme-linked immunosorbent assay (ELISA) was conducted based on previous studies and
manufacturers’ methods [11,13–15]. The PAF level in GCF was measured using an enzyme-linked
immunosorbent assay (ELISA) kit (Biomatik, Cambridge, ON, Canada), as were the cathepsin
B and ICTP levels (Aviva Systems Biology, San Diego, CA, USA). The analysis was performed
according to the manufacturers’ methods. Each sample was added to a microplate well that had been
precoated with affinity polyclonal antibodies specific for PAF, cathepsin B, and ICTP. After washing,
specific enzyme-conjugated polyclonal antibodies and substrate solutions were added to the wells.
After confirming the color change in the reaction (15–30 min), the stop solution was added and the
absorbance was measured at 450 nm in a microplate reader (Infinite M200 PRO NanoQuant microplate
reader, TECAN, Zurich, Switzerland). The sample values were calculated using a standard curve and
the levels of molecular biomarkers were expressed in picograms per milliliter.
The cystatin C, MPO, and MMP-9 levels in saliva were measured using an ELISA kit (R&D
Systems, Minneapolis, MN, USA), as were the lactoferrin and MMP-8 levels in saliva (Biovendor, Brno,
Czech Republic). The analysis was performed according to the manufacturers’ methods. For each
assay, the absorbance was measured at 450 nm and calculated using a standard curve, with the levels
of molecular biomarkers expressed in nanograms per milliliter.
2.6. Statistical Analysis
Commercially available statistical analysis software (IBM SPSS Statistics 23, SPSS, Chicago, IL,
USA) was used to perform the statistical analyses. The Mann–Whitney U test was used to compare
demographic and clinical parameters between the gingivitis and healthy groups. Pearson’s correlation
analysis was used to identify correlations between the biomarker levels and the percentage of BOP
sites. The correlations between clinical parameters and the percentage of BOP sites were also analyzed.
The diagnostic ability of each marker was evaluated by constructing a ROC curve, from which the
AUC was calculated. The sensitivity and specificity were calculated for each point on the ROC curve.




The demographic and clinical parameters of the participants are summarized in Table 1. Among 100
subjects, 85 were diagnosed as gingivitis, and 15 were diagnosed as gingival health. Age, sex, and CAL
did not differ significantly between the healthy and gingivitis groups. As expected, BOP, PI, and GI
were significantly larger in the gingivitis group, while there was no intergroup difference in CAL.
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Table 1. Distribution of study subject characteristics (mean ± standard deviation) in healthy and
gingivitis group.
Healthy Group (n = 15) Gingivitis Group (n = 85) p-Value
Age (years) 34.93 ± 15.79 32.65 ± 12.21 0.85
Female/Male (n) 7/8 47/38 0.54
BOP site (%) 5.56 ± 0.89 26.96 ± 4.70 * <0.001
CAL (mm) 2.55 ± 0.30 2.60 ± 0.27 0.71
PI 0.13 ± 0.22 0.53 ± 0.39 * <0.001
GI 0.39 ± 0.35 0.96 ± 0.37 * <0.001
* Statistically significant difference compared to the healthy group (p < 0.05). BOP, bleeding on probing; CAL,
clinical attachment loss; PI, plaque index; GI, gingival index.
3.2. Correlation Analyses
The coefficients of the biomarkers and clinical parameters are summarized in Table 2.
Since, percentage of BOP sites is the only criterion for clinical diagnosis of gingivitis, correlations of
each biomarkers and percentage of BOP sites were analyzed [17]. MPO was the biomarker that showed
the strongest correlation with the percentage of BOP sites, with a Pearson’s correlation coefficient
of 0.399 (p < 0.01). MMP-8 showed a positive correlation with the percentage of BOP sites, with a
Pearson’s correlation coefficient of 0.217 (p < 0.05). The other analyzed biomarkers did not show
significant correlations with the percentage of BOP sites (p > 0.05).
Table 2. Correlation of clinical parameter and biomarkers with number of BOP sites.
Coefficient of Correlation p-Value
Average plaque index (PI) 0.411 ** <0.001
Average gingival index (GI) 0.766 ** <0.001
Clinical attachment loss (CAL) 0.096 0.346
MPO 0.399 ** <0.001
MMP-8 0.217 * 0.034
MMP-9 0.032 0.750
Cystatin C 0.055 0.595
Lactoferrine 0.137 0.183
PAF 0.034 0.742
Cathepsin B -0.093 0.366
ICTP -0.004 0.966
* Statistically significant correlation (p < 0.05). ** Statistically highly significant correlation (p < 0.01). BOP, bleeding
on probing; MPO, myeloperoxidase; MMP-8, matrix metalloproteinase-8; MMP-9, matrix metalloproteinase-9;
PAF, platelet activating factor; ICTP, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen; BOP,
bleeding on probing; CAL, clinical attachment loss; PI, plaque index; GI, gingival index.
The clinical parameters of GI and PI showed strong correlations with the percentage of BOP sites
(p < 0.01), while CAL did not show any correlation with the percentage of BOP sites.
3.3. ROC Curves
ROC curves of the biomarkers and clinical parameters for gingivitis are shown in Figure 2, and the
corresponding AUC values are summarized in Table 3. MMP-8 was the biomarker that showed
the largest AUC of 0.734, with a cutoff of 6.46 ng/mL. MMP-9 and MPO also showed large AUC
values, of 0.703 and 0.685, respectively, while cystatin C showed an AUC of 0.667. The ROC curves
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for MMP-8, MMP-9, MPO, and cystatin C are shown in Figure 3. The AUC values for lactoferrin,
PAF, ICTP, and cathepsin B levels were lower than 0.5, indicating that these parameters were not
statistically relevant.
Figure 2. Receiver operating characteristic (ROC) curve of clinical parameters and biomarkers.
Only plaque index, gingival index, MMP-8, MMP-9, MPO, and cystatin C showed convex shape
of curve. Concave curve means subject of ROC curve does not have any diagnostic ability. As the
diagnostic power of subject is increased, convexity of ROC curve increases. MPO, myeloperoxidase;
MMP-8, matrix metalloproteinase-8; MMP-9, matrix metalloproteinase-9; GCF, gingival crevicular
fluid; PAF, platelet activating factor; ICTP, pyridinoline cross-linked carboxyterminal telopeptide of
type I collagen.
Figure 3. Receiver operating characteristic (ROC) curve of MMP-8, MMP-9, MPO, and cystatin C.
Area under ROC curve (AUC) is measured based on the curve. The farthest point from standard line is
selected to set cut-off value for diagnosis. MPO, myeloperoxidase; MMP-8, matrix metalloproteinase-8;
MMP-9, matrix metalloproteinase-9.
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Table 3. Receiver operating characteristic (ROC) area under curve (AUC) of biomarkers and clinical
parameters. Sensitivity and specificity of each biomarker were selected at the cut-off value points of the
ROC curve.
AUC Cut-Off Value (ng/mL) Sensitivity Specificity
MMP-8 0.734 6.464 0.87 0.60
MMP-9 0.703 38.075 0.739 0.63
MPO 0.685 12.75 0.87 0.42
Cystatin C 0.667 59.28 0.725 0.59
MPO, myeloperoxidase; MMP-8, matrix metalloproteinase-8; MMP-9; matrix metalloproteinase-9.
The AUC values of the clinical parameters are summarized in Table 4. GI and PI showed large
AUC values of 0.788 and 0.692, respectively, while that of CAL was 0.532, indicating that this was not
suitable for diagnosing gingivitis.




Clinical attachment loss 0.532
4. Discussion
This study demonstrated that the MMP-8 and MPO levels are suitable for diagnosing gingivitis
based on significant results obtained in both correlation and ROC curve analyses. In contrast to most
previous studies focusing on differences in the concentrations of biomarkers between periodontitis
and healthy groups, our study evaluated and compared the diagnostic powers of different biomarkers
for gingivitis [11,13,15,20]. Few previous studies have focused on diagnosing gingivitis. One study
included an experimental gingivitis group, but the evaluation of the diagnostic abilities of biomarkers
was limited to the periodontitis group only [21].
Gingivitis has been defined as “an inflammatory lesion which remains confined to the gingiva
and does not extend to the periodontal attachment (cementum, periodontal ligament and alveolar
bone). Such inflammation is reversible by reducing levels of dental plaque at and apical to the
gingival margin” [17]. As this definition implies, gingivitis itself is not a state of tissue destruction
and is reversible to a healthy state. Gingivitis usually shows clinical features such as redness and
swelling, but it is commonly painless, which means that most affected patients are not aware of it [22].
However, since untreated gingivitis may progress to periodontitis accompanied by irreversible tissue
destruction, it is important to diagnose periodontal disease at the gingivitis stage before the patient
experiences clear symptoms or the loss of periodontal attachment occurs [3]. It is therefore desirable to
identify biomarkers for the early detection of gingivitis before it progresses to periodontitis.
Previous studies have found that the concentrations of numerous oral fluid biomarkers differ
between normal and periodontitis groups [10,11,13,14,23]. A statistically significant difference
in concentrations or a strong correlation shows the possibility of applying such biomarkers to
disease diagnosis. However, the presence of such a concentration difference between healthy and
diseased groups does not imply that a particular biomarker has a strong diagnostic ability [24].
Instead, the clinical utility of a biomarker in diagnoses is related to its ability to discriminate between
patients who have and those who do not have a disease according to criteria based on the concentration
of the biomarker. Thus, the pure existence of a difference between healthy and diseased groups does
not fulfill the conditions of a biomarker being appropriate for diagnoses, since both clinical relevance
and validity are also needed [25].
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An ROC curve is a plot of sensitivity versus 1 minus specificity, and it is one of the most popular
and effective methods for evaluating the discrimination ability of a diagnosis model [26]. In detail,
an ROC curve can provide evidence for optimal cutoff values for a dichotomous diagnosis, and the
corresponding AUC is considered an effective parameter for comparing the accuracies of different
diagnostic models [27]. The construction of a ROC curve involves plotting multiple points rather than
making a single measurement, which provides the advantage of the AUC being independent of any
particular reference value used in a diagnosis and so is suitable for evaluating and comparing utility of
different biomarkers in different units.
MMP-8 showed the largest AUC and strongest correlation with gingivitis in this study. MMP-8 is
one of the most widely studied host-derived enzymes as a biomarker for periodontal disease, which is
related to tissue destruction [9,15,28]. In a state of periodontal disease, neutrophil and macrophages
release MMPs as part of the host response [20]. Among MMPs, MMP-8 degrades collagen types 1 and
3, which are major components of periodontal tissues [28]. Previous studies have found that individual
patients diagnosed with periodontitis showed significant elevations of the MMP-8 concentration
compared to healthy groups [12,15]. Also, MMP-8 can be used to predict the progression of periodontal
disease or the response to periodontal therapy [19,29].
MPO also showed a large AUC and a strong correlation with gingivitis in the present study.
A previous study observed a difference in MPO concentration between healthy and chronic periodontitis
group [13]. MPO is expressed from phagosome of neutrophils and reacts with hydroxyl peroxide to
form metabolites that play a significant role in bactericidal activity [30]. Since MPO mediates MMP-8
activation and collagenolytic MMP activation cascade, MPO produced in initial immune response of
neutrophil amplifies the tissue destructive process [31]. Conversely, elevated concentration of MPO
itself can reinforce pathogenic challenge or gingival inflammation. A recent study suggested that high
a concentration of MPO can contribute to dysbiosis of the gingival sulcus microbiome [32].
Leppilahti et al. found that the MMP-8 and MPO levels in GCF showed large AUC values for the
diagnosis of chronic periodontitis, of 0.90 and 0.98, respectively, with cutoff values of 2520.6 ng/mL
and 135.9 ng/mL, which produced sensitivities and specificities of around 0.9 [13]. MMP-8, MMP-9,
and MPO showed smaller AUC values and lower cutoff values in the present study. Also, the diagnostic
sensitivity was similar, but the diagnostic specificity was significant lower in our study than in that
of Leppilahti et al. These differences in diagnostic power are due to the differences in the targeted
diseases: the diagnosis target in the previous study was periodontitis, while that in our study was
gingivitis, which is a mild and early state of periodontitis. Differences in the severity of periodontal
inflammation result in differences in the variety and concentrations of inflammatory substances [33].
Thus, gingivitis shows lower concentrations of inflammatory biomarkers compared to periodontitis,
and diagnostic biomarkers are more difficult to identify when their concentrations are lower in
the diseased state due to the inevitable noise in tests affecting the results more when the reference
concentration is low. Also, performing diagnoses with a low reference concentration is vulnerable to
external confounding factors such as fluctuations in the general condition and contamination of the
sample fluid. The consequence of all of these factors make that it is difficult for a diagnostic model
with a low reference concentration to be clear and powerful, as represented by a large AUC.
An ideal diagnostic model would have a high sensitivity and specificity simultaneously, but a
diagnostic model with a high sensitivity and low specificity can be a better alternative to one with
a low sensitivity and high specificity [34]. In the case of the gingivitis, in which early intervention
is especially important, and treatment or a diagnostic test is not invasive or risky to patients, a false
negative is more problematic than a false positive. Also, treating gingivitis using methods such as
scaling as part of maintenance therapy does not have harmful effects on patients.
Clarifying the biomarkers of gingivitis can be the basis for future studies that clearly identify the
effect of dietary intake of micronutrients on periodontal health. It is widely accepted that micronutrient
supplements, such as vitamins, can induce alterations of the inflammatory cascade and reduce chronic
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inflammation as a result [35]. Supporting studies evaluated periodontal health or inflammation by
probing-based conventional clinical methods or changes of certain oral fluid biomarkers [36,37].
However, in a probing-based evaluation, there is limitation of standardization due to intra- and
inter-examiner variation [38]. Also, in case of mild inflammation such as gingivitis, it is difficult to
discriminate BOP due to actual inflammatory and BOP due to trauma of periodontal probing which is
false positive [6,39]. In biomarker-based evaluation, previously documented oral fluid biomarkers
showed a difference in concentration between periodontitis diagnosed patients and healthy individual.
Since gingivitis is prerequisite to periodontitis, it seems to be natural to regard that both gingivitis and
periodontitis can share diagnostic biomarkers. However, there is difference in severity and stage of
inflammation, therefore it could be impractical to regard all diagnostic biomarkers for periodontitis to
have proper diagnostic ability in gingivitis. To the best of our knowledge, there was not any study that
aims to confirm biomarkers for gingivitis with a large sample size. The sample size of this study was
sufficient, thus the result of this study can contribute to clarifying biomarkers of gingivitis.
In summary, MMP-8 and MPO have now been shown to be effective in diagnosing gingivitis.
Nevertheless, since gingivitis is a milder and earlier inflammatory state compared to periodontitis,
a biomarker-based diagnosis method for gingivitis needs to be more sensitive. Further investigations
based on the findings of this study may lead to clinical diagnosis methods based on biomarkers that
facilitate the accurate and early detection
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